Sun Pharma to acquire Russia's JSC Biosintez; shares up
“With this move, we plan to acquire the product portfolio and local manufacturing capability in Russia which would help in expanding our presence in Russia and serving Russia pharmaceutical market more effectively,” Sun Pharma said in a statement.
)
10:10 AM IST
Sun Pharmaceuticals on Wednesday said that it has entered into an agreement to acquire 85.1% of JSC Biosintez – a Russian pharma company.
“With this move, we plan to acquire the product portfolio and local manufacturing capability in Russia which would help in expanding our presence in Russia and serving Russia pharmaceutical market more effectively,” Sun Pharma said in a statement.
The deal will involve cost acquisition of approximately RUB 1526 million ($24 million). Sun Pharma will also assume a debt of about $ 36 million as a part of the transaction.
Shares of Sun Pharma was trading at Rs 693.60 per share on BSE, up Rs 4 or 0.56%.
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.
RECOMMENDED STORIES
)
)
)
)
)
)
)
)
)
)
)
Sun Pharma Share Price: Stock cracks nearly 5% post Q4; analysts slash targets despite margin beat
Sun Pharma Q4 FY25 Results: PAT falls 19%, disappoints analysts; 550% dividend declared 
Final Trade: Sensex up 410 pts, Nifty closes at 24,813; Realty, pharma stocks shine, but volatility keeps bulls in check
